Yoga for Pain and Opioid Dependence (Yoga)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01590251|
Recruitment Status : Completed
First Posted : May 2, 2012
Last Update Posted : September 25, 2015
|Condition or disease||Intervention/treatment||Phase|
|Chronic Pain Opioid Addiction||Other: Yoga Behavioral: Educational Counseling||Phase 1 Phase 2|
This study aims to develop an adjunctive novel treatment intervention using yoga in opioid agonist maintained patients to effectively treat the co-occurring disorders of non-malignant chronic pain and opioid dependence (POD).
1) To conduct a pre-pilot phase with 8 patients with POD receiving opioid agonist maintenance treatment.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||8 participants|
|Intervention Model:||Factorial Assignment|
|Masking:||None (Open Label)|
|Official Title:||Yoga for Pain and Opioid Dependence|
|Study Start Date :||April 2012|
|Actual Primary Completion Date :||November 2014|
|Actual Study Completion Date :||November 2014|
Gentle yoga for chronic pain and opioid dependence
Two yoga sessions per week for 8 weeks (one yoga session is instructional, the other is a practice session.
Active Comparator: Educational Counseling
Educational counseling is a didactic, lecture-discussion format to supplement the information and advice provided in opioid agonist maintenance treatment.
Behavioral: Educational Counseling
One didactic session per week of approximately 50 minutes that provides information about chronic pain and substance abuse disorders.
- Pain reduction [ Time Frame: 8 weeks ]Pain reduction will be measured by patient self-report using standard pain rating scales.
- Reduce illicit opioid use [ Time Frame: 8 weeks ]Reduced illicit opioid use will be measured by patient self-report and urinalysis testing.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01590251
|United States, Connecticut|
|New Haven, Connecticut, United States, 06519|
|Principal Investigator:||Declan T Barry, Ph.D.||Yale University|